Besides, elevated plasma IL‐6 levels have been consistently associated with the resistance to antitumour treatment and poorer prognoses in NSCLC, suggesting its potential as a therapeutic target, especially for NSCLC patients with cachexia and elevated plasma IL‐6 levels [7, 8]. Here, IL6 is linked to non-small cell lung carcinoma.